These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28685863)

  • 1. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.
    Baertsch MA; Hillengass J; Blocka J; Schönland S; Hegenbart U; Goldschmidt H; Raab MS
    Hematol Oncol; 2018 Feb; 36(1):210-216. PubMed ID: 28685863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panobinostat for the Treatment of Multiple Myeloma.
    Laubach JP; Moreau P; San-Miguel JF; Richardson PG
    Clin Cancer Res; 2015 Nov; 21(21):4767-73. PubMed ID: 26362997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
    Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
    Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.
    Greig SL
    Target Oncol; 2016 Feb; 11(1):107-14. PubMed ID: 26826025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
    Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
    Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Haematol; 2016 Nov; 3(11):e506-e515. PubMed ID: 27751707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
    Wahaib K; Beggs AE; Campbell H; Kodali L; Ford PD
    Am J Health Syst Pharm; 2016 Apr; 73(7):441-50. PubMed ID: 27001985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
    Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
    Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deacetylase inhibitors: an advance in myeloma therapy?
    Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
    Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
    J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
    Richardson PG; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Corrado C; Binlich F; San-Miguel JF
    Blood; 2016 Feb; 127(6):713-21. PubMed ID: 26631116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
    Richardson PG; Schlossman RL; Alsina M; Weber DM; Coutre SE; Gasparetto C; Mukhopadhyay S; Ondovik MS; Khan M; Paley CS; Lonial S
    Blood; 2013 Oct; 122(14):2331-7. PubMed ID: 23950178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
    Tzogani K; van Hennik P; Walsh I; De Graeff P; Folin A; Sjöberg J; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):631-636. PubMed ID: 29192015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.
    San-Miguel JF; Einsele H; Moreau P
    Adv Ther; 2016 Nov; 33(11):1896-1920. PubMed ID: 27677481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
    Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
    JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panobinostat for the management of multiple myeloma.
    Sivaraj D; Green MM; Gasparetto C
    Future Oncol; 2017 Mar; 13(6):477-488. PubMed ID: 27776419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
    Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
    Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
    Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R; Anderson KC; Lonial S
    Leuk Lymphoma; 2012 Sep; 53(9):1820-3. PubMed ID: 22288662
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
    Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
    Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.